Journal of the American Chemical Society · 1999 · 57 citations · 19 references
Life SciencesBiochemistryMolecular BiologyMolecular VirologyStructural BiologyVirologyAntiretroviral TherapyAntiviral PharmacologyEnzyme InhibitionProtein StructureProtein Structure ModelingProteolytic Enzymes3D Molecular ModelingAntiviral Structure-activity RelationshipsProtease Inhibitor ResistanceProtease InhibitorsViral Protease InhibitionViral Proteases
Based on the structural analysis of FIV protease and drug-resistant HIV proteases and molecular modeling, a new type of inhibitors with a small P3 residue has been developed. These inhibitors are effective against HIV and its drug-resistant mutants, as well as SIV and FIV. Modification of existing HIV protease inhibitors by reducing the size of the P3 residue has the same effect. This finding provides a new strategy for the development of HIV protease inhibitors effective against the wild-type and drug-resistant mutants. It further supports the use of FIV protease as a useful model for drug-resistant HIV proteases, which often have a more constricted binding region for the P3 group or the combined P3 and P1 groups.
19
In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
Jon H. Condra, William A. Schleif, O M Blahy et al. · Nature · 1995 · 979 citations